Clinical trial

GLP-1s in Hip and Knee Arthroplasty

Opening soon · Phase 4 · 1 countries · Registry ID NCT07755085

Opening soonPhase 4Interventional

What this study is about

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 90 Years

SexAll

Healthy volunteersNot accepted

ConditionArthritis, Obesity & Overweight, GLP - 1

Full registry criteria

Inclusion Criteria: * Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon * Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+ * Patients must be between 18-90 years of age * Able to provide informed consent Exclusion Criteria: * Cognitive impairment that precludes study participation and compliance * Patients unwilling to undergo smoking cessation prior to surgery * Patients currently taking biologic medications that suppress the immune system * Patients currently taking GLP-1 medications * Patients with a contraindication to GLP-1 medication

Treatments and study arms

GLP-1 Receptor Agonists + Behavioral modification

Drug

At least 6 months of preoperative semaglutide and structured behavioural modification

Behavioral + placebo

Behavioral

Structured behavioural modification - diet, exercise, counselling and placebo medication

Primary outcomes

Incidence of Wound Complication after Joint Arthroplasty90 days

To determine whether the preoperative administration of a GLP-1 receptor agonist impacts the incidence of wound complications in patients with class 3 or 4 obesity that require either antibiotics, in clinic debridement or a return to the operating room within 90 days of THA or TKA (Yes/No)

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Nova Scotia Health🇨🇦 Dartmouth, Nova Scotia, Canada

Open map

Jhase Sniderman, MD,MSc, FRSCS, FAAOSContact

Email · Call 9029323130